Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor.
Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference.
Know Labs reported a mean absolute relative difference (MARD) — a measure of accuracy — of 11.1%. Comparatively, market-leading minimally invasive CGMs from Dexcom and Abbott have demonstrated higher levels of accuracy. Dexcom’s G7 previously demonstrated a MARD of 8.2%, while Abbott’s FreeStyle Libre 3 came in at 7.6%.
However, Know Labs’ non-invasive offering remains an interesting prospect, given there are no FDA-cleared CGMs of this kind at present. Larry Ellingson, a Know Labs board member, highlighted the importance of this initial data.
“Achieving this level of accuracy in the first study using a blood reference device is truly remarkable,” Ellingson said in a news release. He previously served as chair of the board of the American Diabetes Association.
The company last week raised $12 million to work toward bringing its non-invasive CGM technology to market. The company unveiled KnowU, its wearable CGM set for FDA submission, last month.
Get the full story at our sister site, Drug Delivery Business News.